Showing results (391-400 of 1,625) with videos related to
Sort By:
Pageof 163
Kidney International. Supplement|November 2, 2002
Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenonWajeh Y Qunibi, Charles A Nolan, J Carlos AyusKidney International. Supplement|November 2, 2002
Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertensionEva Cediel, Beatriz Vázquez-Cruz, Josefa Navarro-Cid, et al.Kidney International. Supplement|November 2, 2002
Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damageSaulo Klahr, Jeremiah MorrisseyKidney International. Supplement|November 2, 2002
Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathySandra Blanco, Rosa Penin, Irma Casas, et al.Kidney International. Supplement|November 2, 2002
Role of calcium channel blockers in the future, in view of the INSIGHT StudyTalma RosenthalKidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.Kidney International. Supplement|September 17, 2002
Pharmacokinetics of icodextrin in peritoneal dialysis patientsJames B Moberly, Salim Mujais, Todd Gehr, et al.Kidney International. Supplement|May 20, 2003
Chromosomal aberrations, the consequence of refractory hyperparathyroidism: its relationship with biochemical parametersSandra Afonso, Iñigo Santamaría, Martín E Guinsburg, et al.Kidney International. Supplement|May 20, 2003
Selective estrogen receptor modulators in chronic renal failureJosé R Weisinger, Ita Pfeferman Heilberg, Eddy Hernández, et al.Kidney International. Supplement|May 20, 2003
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patientsPatrick C D'Haese, Goce B Spasovski, Aleksander Sikole, et al.Pageof 163